AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 31 min read$CORT

Corcept: Q3 Earnings Snapshot

Corcept Therapeutics (CORT) reported Q3 earnings of $124.5M, or $1.01 per share, beating estimates of 68 cents. Revenue was $340.5M, exceeding forecasts of $329.2M.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Corcept: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$CORTBullishMed
01

Why it matters

The earnings beat could attract short-term buying interest and may lift the stock in after-hours trading.

02

Market read

First-report earnings beat for a mid-cap biotech, offering a fresh trading catalyst.

03

What to watch

Guidance outlook not disclosed; future performance uncertain.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

Corcept Therapeutics (CORT) is a specialty pharmaceutical company focused on developing treatments for endocrine disorders.

Company-level read

Ticker impact

$CORTBullishHigh confidence
Context

Corcept Therapeutics reported Q3 earnings and revenue that both beat analyst expectations.

Expected impact

upward pressure as market prices in the earnings beat

Evidence & confidence

Revenue and EPS exceeded consensus, suggesting stronger performance than anticipated.

Market effects

Sector

Positive for specialty pharma and biotech peers.

Regional

U.S. biotech sector may see modest gains.

Global

Limited to investors tracking U.S. biotech earnings.

Counterpoint

What could challenge this read

Beat may be priced in quickly; watch for profit-taking.

Key entities

  • Company
    Corcept Therapeutics Inc.

    Issuer of the earnings report.

Read at source← All news

StoryCorcept Therapeutics posts Q3 earnings beat, keeps 2026 revenue guidance and awaits FDA decision

Also covered by

4 outlets

Related articles

NOV 4
$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.

finance.yahoo.com3 min
NOV 3
$CORTHighAI 8/10

Corcept’s (NASDAQ:CORT) Q3 2026: beats on revenue

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $340.5M, up 64% YoY and 1.9% above estimates. EPS of $1.01 beat estimates by 27.2%. The company reconfirmed its full-year revenue guidance of $1.15B. Operating margin improved to 33.7% YoY. CEO highlights growth in endocrinology and ovarian cancer treatments.

finance.yahoo.com2 min
NOV 3
$CORTMed

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

CORCEPT THERAPEUTICS INC (CORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update • Revenue of $340.5 million, a 64 percent increase over the same period in 2025 ◦ Korlym ® and authorized generic product revenue of $249.1 million ◦ Lifyorli ® product reven

SEC EDGAR 8-K2 min